Cargando…
Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
Autores principales: | Castillo, Jorge J, Kingsley, Edwin C, Narang, Mohit, Yimer, Habte A, Dasanu, Constantin A, Melear, Jason M, Coleman, Morton, Farber, Charles M, Shulman, Jonah, Mantovani, Emily H, Zhang, Xiaowei, Cohen, Aileen, Huang, Jane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928654/ https://www.ncbi.nlm.nih.gov/pubmed/36819162 http://dx.doi.org/10.1002/jha2.619 |
Ejemplares similares
-
P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Castillo, J. J., et al.
Publicado: (2022) -
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022) -
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013) -
Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)